Earnings Call · Q2 FY2026·2026-07-30

Q2 26EPS +56.63%·Rev n/aQ1 26EPS +6.40%·Rev n/aQ4 25EPS +6.42%·Rev n/aQ3 25EPS +22.72%·Rev n/a⚠ consensus missing

REGENERON PHARMACEUTICALS, INC. REGN

Michelle — Operator

Ryan Crowe — Senior Vice President, Investor Relations

Dr. Leonard Schleifer — Co-founder, Board Co-Chair, President and Chief Executive Officer

Dr. George Yancopoulos — Co-founder, Board Co-Chair, President and Chief Scientific Officer

Marion McCourt — Executive Vice President, Commercial

Chris Fenimore — Executive Vice President, Finance and Chief Financial Officer

+6.2%1d on move date3d+9.2%5d+10.5%

Research tier

Behavioral profile computed for 6 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more REGN calls or request research access.

More REGN calls Browse calls Request research access